Clinical Research Genetics Medicine Pharma Companies 
XTalks
JANUARY 15, 2024
The field of clinical research will witness significant advancements in 2024. Read on to learn about the top 10 clinical trial trends for 2024, and be sure to explore and join upcoming webinars about clinical trials at Xtalks. Blockchain can enhance data security and compliance by creating immutable data records.
Cloudbyz
SEPTEMBER 25, 2020
Time is also of the essence in drug development, as competitive product-to-market lead times help pharma companies improve profitability. Time spent on clinical trials involves investment and being able to predict ADRs assists with improving the success rate. MEDIKURA Digital Health – Post-Market Drug Safety.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
SEPTEMBER 28, 2022
Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace. This is where ‘swarm learning’, which is predicted to change the way the biotech sector operates, comes in.
Pharmaceutical Technology
JUNE 15, 2023
Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S. Pharma companies need tools like AI that can reliably improve this percentage without jeopardizing safety. Learn more about the benefits and challenges of AI and clinical trials, as well as examples of AI’s use in this industry.
pharmaphorum
DECEMBER 21, 2021
Additionally, the work being done within Rare Disease networks, formed of specialty sites, pharma companies, CROs, researchers, and other stakeholders, can all benefit from the value generated by real world genomic data, as outlined by panellist Dr Joanne Hackett, Head of Genomic and Precision medicine at IQVIA.
XTalks
DECEMBER 20, 2023
Check out this article to learn about the biotech companies that went public this year. The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy.
Cloudbyz
MAY 19, 2021
Moreover, 12% of industrial clinical pipeline products and at least 16% of preclinical pipeline products consist of CGT. The primary drivers for growth include increasing cancer and genetic cases and predicated applicability of CGT as a treatment.
Expert insights. Personalized for you.
105 
Let's personalize your content